Tenderwize
Retour à la recherche

Pharmaceutical supply agreements

BARMER Beschaffung und Vergabe·Wuppertal, Germany·EUR 39.5M·Deadline Feb 01, 2028 · 521 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarder
High valueStructured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption

45/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

45 / 100

Complexité

35 / 100

Facteurs de risque

The notice explicitly states it is not a public procurement under EU directives, which may limit legal recourse and pro...

No award criteria or selection criteria are provided. The evaluation method is unknown.

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • EUR 39.5M estimated value
  • Framework procurement
  • Supplies contract
  • 2 lots
  • Duration until Mar 2028
  • Supply of pharmaceutical products containing Lanreotide
  • Supply of pharmaceutical products containing Triptorelin
Afficher le résumé complet

This notice concerns framework agreements with accession option for pharmaceutical products containing active substances Lanreotide and Triptorelin. The buyer explicitly states this is not a public procurement under EU directives, but uses the open procedure form. Two lots with total estimated value of EUR 39,460,246.57. Duration 2 years from April 2026 to March 2028. Submission deadline is 1 February 2028. Only German language. No explicit award or selection criteria provided.

Risques

The notice explicitly states it is not a public procurement under EU directives, which may limit legal recourse and pro...

No award criteria or selection criteria are provided. The evaluation method is unknown.

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Active substance must be Lanreotide or Triptorelin
  • Framework agreement with accession option
  • Supply to Wuppertal, Germany

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Wuppertal, DEU

Identifiant

992-80322-57

Activité

Health

Lots (2)

LOT-0001

Lanreotid

Framework agreement for pharmaceuticals containing Lanreotide. Estimated value EUR 33,819,814.39. Place of performance: Wuppertal, Germany. Duration: 2026-04-01 to 2028-03-31.

SuppliesFrameworkEU fundedElectronic submission

EUR 33.8M

Valeur estimée

Localisation

Wuppertal, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 01, 2028

LOT-0002

Triptorelin

Framework agreement for pharmaceuticals containing Triptorelin. Estimated value EUR 5,640,432.18. Place of performance: Wuppertal, Germany. Duration: 2026-04-01 to 2028-03-31.

SuppliesFrameworkEU fundedElectronic submission

EUR 5.6M

Valeur estimée

Localisation

Wuppertal, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 01, 2028

Détails de la procédure

Date de publication
17 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
114335-2026

Documents (1)

Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30